Prolonged Oral Etoposide in Recurrent or Advanced Leiomyosarcoma of the Uterus: A Gynecologic Oncology Group Study
Open Access
- 31 August 1998
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 70 (2) , 267-271
- https://doi.org/10.1006/gyno.1998.5080
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- A Phase II Trial of Prolonged Oral Etoposide (VP-16) as Second-Line Therapy for Advanced and Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group StudyGynecologic Oncology, 1996
- The Secondary Leukemias: Challenges and Research DirectionsJNCI Journal of the National Cancer Institute, 1996
- Prolonged Stabilization of Progressive Endometrial Stromal Sarcoma with Prolonged Oral Etoposide TherapyGynecologic Oncology, 1995
- Prolonged Oral Etoposide for Refractory Advanced Uterine LeiomyosarcomaGynecologic Oncology, 1995
- A Case of Recurrent Intramural Uterine Stromal Tumor with Epithelial Differentiation Effectively Treated with Oral Low‐Dose Administration of EtoposideAsia-Oceania Journal of Obstetrics and Gynaecology, 1994
- Oral Etoposide in Treatment of Advanced Refractory SarcomasJNCI Journal of the National Cancer Institute, 1992
- Chronic daily administration of oral etoposide in refractory lymphomaEuropean Journal of Cancer and Clinical Oncology, 1990
- VP-16 in advanced soft tissue sarcoma: A phase II study of the EORTC soft tissue and bone sarcoma groupEuropean Journal of Cancer and Clinical Oncology, 1987
- SCHEDULE DEPENDENCY OF THE ANTILEUKEMIC ACTIVITY OF THE PODOPHYLLOTOXIN‐DERIVATIVE VP 16–213 (NSC‐141540) IN L1210 LEUKEMIAActa Pathologica Microbiologica Scandinavica Section A Pathology, 1973
- Sarcoma of the UterusObstetrics & Gynecology, 1962